WO2006012642A3 - Pyrrole derivatives as pharmaceutical agents - Google Patents

Pyrrole derivatives as pharmaceutical agents Download PDF

Info

Publication number
WO2006012642A3
WO2006012642A3 PCT/US2005/026916 US2005026916W WO2006012642A3 WO 2006012642 A3 WO2006012642 A3 WO 2006012642A3 US 2005026916 W US2005026916 W US 2005026916W WO 2006012642 A3 WO2006012642 A3 WO 2006012642A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical agents
pyrrole derivatives
receptors
activity
modulating
Prior art date
Application number
PCT/US2005/026916
Other languages
French (fr)
Other versions
WO2006012642A2 (en
Inventor
Bannen Lynne Canne
Jeff Chen
Lisa Esther Dalrymple
Brenton T Flatt
Timothy Patrick Forsyth
Xiao-Hu Gu
Morrison B Mac
Larry W Mann
Grace Mann
Richard Martin
Raju Mohan
Brett Murphy
Michael Charles Nyman
William C Stevens Jr
Tie-Lin Wang
Yong Wang
Jason H Wu
Original Assignee
Exelixis Inc
Bannen Lynne Canne
Jeff Chen
Lisa Esther Dalrymple
Brenton T Flatt
Timothy Patrick Forsyth
Xiao-Hu Gu
Morrison B Mac
Larry W Mann
Grace Mann
Richard Martin
Raju Mohan
Brett Murphy
Michael Charles Nyman
William C Stevens Jr
Tie-Lin Wang
Yong Wang
Jason H Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US59243904P priority Critical
Priority to US59246904P priority
Priority to US60/592,439 priority
Priority to US60/592,469 priority
Application filed by Exelixis Inc, Bannen Lynne Canne, Jeff Chen, Lisa Esther Dalrymple, Brenton T Flatt, Timothy Patrick Forsyth, Xiao-Hu Gu, Morrison B Mac, Larry W Mann, Grace Mann, Richard Martin, Raju Mohan, Brett Murphy, Michael Charles Nyman, William C Stevens Jr, Tie-Lin Wang, Yong Wang, Jason H Wu filed Critical Exelixis Inc
Priority claimed from CN200580026842.3A external-priority patent/CN101006052B/en
Publication of WO2006012642A2 publication Critical patent/WO2006012642A2/en
Publication of WO2006012642A3 publication Critical patent/WO2006012642A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
PCT/US2005/026916 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents WO2006012642A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US59243904P true 2004-07-30 2004-07-30
US59246904P true 2004-07-30 2004-07-30
US60/592,439 2004-07-30
US60/592,469 2004-07-30

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
DK05803281.4T DK1773768T3 (en) 2004-07-30 2005-07-30 PYRROLD DERIVATIVES AS PHARMACEUTICAL AGENTS
CA2573426A CA2573426C (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
KR1020077004302A KR101155288B1 (en) 2004-07-30 2005-07-30 Pyrrole Derivatives as Pharmaceutical Agents
ES05803281T ES2697524T3 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
JP2007523832A JP4703649B2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
RU2007107388/04A RU2470916C2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as medicinal substances
CN200580026842.3A CN101006052B (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
NZ552632A NZ552632A (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
BRPI0513677A BRPI0513677B8 (en) 2004-07-30 2005-07-30 pyrrole derivatives as pharmaceutical agents
LTEP05803281.4T LT1773768T (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
EP05803281.4A EP1773768B8 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
AU2005266890A AU2005266890C1 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
US11/572,962 US8026237B2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
PL05803281T PL1773768T3 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
SI200532237T SI1773768T1 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
IL180630A IL180630A (en) 2004-07-30 2007-01-10 Pyrrole derivatives as pharmaceutical agents
NO20070910A NO344324B1 (en) 2004-07-30 2007-02-16 Pyrrole derivatives as pharmaceuticals
US13/214,665 US8367667B2 (en) 2004-07-30 2011-08-22 Pyrrole derivatives as pharmaceutical agents
CY181101235T CY1120922T1 (en) 2004-07-30 2018-11-21 PYRROL PRODUCTS AS PHARMACEUTICAL AGENTS

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/572,962 A-371-Of-International US8026237B2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents
US13/214,665 Division US8367667B2 (en) 2004-07-30 2011-08-22 Pyrrole derivatives as pharmaceutical agents

Publications (2)

Publication Number Publication Date
WO2006012642A2 WO2006012642A2 (en) 2006-02-02
WO2006012642A3 true WO2006012642A3 (en) 2006-07-27

Family

ID=35786783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026916 WO2006012642A2 (en) 2004-07-30 2005-07-30 Pyrrole derivatives as pharmaceutical agents

Country Status (21)

Country Link
US (2) US8026237B2 (en)
EP (1) EP1773768B8 (en)
JP (2) JP4703649B2 (en)
KR (1) KR101155288B1 (en)
AU (1) AU2005266890C1 (en)
BR (1) BRPI0513677B8 (en)
CA (1) CA2573426C (en)
CY (1) CY1120922T1 (en)
DK (1) DK1773768T3 (en)
ES (1) ES2697524T3 (en)
HU (1) HUE041596T2 (en)
IL (1) IL180630A (en)
LT (1) LT1773768T (en)
NO (1) NO344324B1 (en)
NZ (1) NZ552632A (en)
PL (1) PL1773768T3 (en)
PT (1) PT1773768T (en)
RU (1) RU2470916C2 (en)
SG (1) SG155188A1 (en)
SI (1) SI1773768T1 (en)
WO (1) WO2006012642A2 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027546T2 (en) 2003-08-29 2016-10-28 The Brigham And Women's Hospital Inc Hydantoin derivatives as inhibitors of cellular necrosis
SE0302573D0 (en) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AT545644T (en) 2004-09-24 2012-03-15 Astrazeneca Ab BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND APPLICATIONS THEREOF
DE10354060A1 (en) * 2003-11-19 2005-06-02 Merck Patent Gmbh pyrrole
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
JP4703649B2 (en) * 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド Pyrrole derivatives as pharmaceutical agents
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074244A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
KR101302627B1 (en) 2005-01-05 2013-09-10 아비에 인코포레이티드 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20110144128A1 (en) * 2005-01-10 2011-06-16 Exelixis, Inc. Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
AP2527A (en) 2006-10-31 2012-12-06 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptorantagonists
BRPI0809656B8 (en) * 2007-04-09 2021-05-25 Daiichi Sankyo Co Ltd atropisomer, compound, prophylactic or therapeutic agent, and pharmaceutical composition
WO2009023272A1 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
JP5736098B2 (en) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド Pharmaceutical composition for treating central nervous system disorders
CA2696429A1 (en) * 2007-08-22 2009-02-26 Allergan, Inc. Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
RU2465272C2 (en) 2007-09-10 2012-10-27 КалсиМедика, Инк. Compounds modulating intracellular calcium
US8389567B2 (en) * 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
PL2274303T3 (en) * 2008-03-31 2013-03-29 Teva Pharma Processes for preparing sunitinib and salts thereof
GB0808282D0 (en) * 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CA2734154C (en) 2008-08-15 2017-07-11 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
WO2010019905A1 (en) 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
EP2315590B1 (en) 2008-08-15 2012-09-26 N30 Pharmaceuticals, LLC Pyrrole inhibitors of s-nitrosoglutathione reductase
WO2010027875A2 (en) * 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
KR101643285B1 (en) * 2008-10-08 2016-07-29 엑셀리시스, 인코포레이티드 Atropisomers of (hydroxyalkyl)pyrrole derivatives
CN102177137B (en) * 2008-10-08 2015-03-18 埃克塞利希斯股份有限公司 1-phenylpyrrole compounds
EP3000468A1 (en) 2008-12-23 2016-03-30 President and Fellows of Harvard College Small molecule inhibitors of necroptosis
WO2010107476A1 (en) * 2009-03-19 2010-09-23 Duke University Inhibiting gsnor
AU2010245072B2 (en) * 2009-05-05 2013-11-28 Merck Sharp & Dohme Corp. p38 kinase inhibiting agents
EP2253617A1 (en) * 2009-05-20 2010-11-24 Bayer CropScience AG Halogenated compounds as pesticides
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
WO2011034962A2 (en) * 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
TWI532725B (en) * 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
ES2566934T3 (en) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and / or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
JP5916149B2 (en) 2010-08-27 2016-05-11 カルシメディカ，インク． Compounds that regulate intracellular calcium
US20140113898A1 (en) * 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
CA2856946C (en) 2011-12-02 2016-08-02 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases
ES2797123T3 (en) 2011-12-21 2020-12-01 Novira Therapeutics Inc Antiviral agents for hepatitis B
EA027280B1 (en) 2012-08-28 2017-07-31 Янссен Сайенсиз Айрлэнд Юси Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
PL2961732T3 (en) 2013-02-28 2017-09-29 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
AU2014247138B2 (en) 2013-04-03 2018-06-28 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
KR20210018557A (en) 2013-04-10 2021-02-17 다이이찌 산쿄 가부시키가이샤 Crystal of pyrrole derivative and method for producing the same
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP3025711B1 (en) 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medicine for preventing or treating hypertension
JP6348978B2 (en) 2013-07-25 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー Glyoxamide-substituted pyrrolamide derivatives and their use as pharmaceuticals for treating hepatitis B
HUE037007T2 (en) 2013-08-27 2018-08-28 Daiichi Sankyo Co Ltd Method for producing pyrrole derivative, and intermediate thereof
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015083130A1 (en) * 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN106232136A (en) 2014-02-05 2016-12-14 诺维拉治疗公司 For treating the conjoint therapy of HBV infection
UY35980A (en) 2014-02-06 2015-08-31 Janssen Sciences Ireland Uc DERIVATIVES OF SULFAMOILPIRROLAMIDA AS INHIBITORS OF HBV AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SG11201704764PA (en) 2014-12-11 2017-07-28 Harvard College Inhibitors of cellular necrosis and related methods
KR20170104486A (en) * 2015-01-26 2017-09-15 다이이찌 산쿄 가부시키가이샤 Solid composition of pyrrole carboxamide
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TWI623316B (en) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2017151786A1 (en) 2016-03-01 2017-09-08 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
KR20180123021A (en) 2016-03-24 2018-11-14 다이이찌 산쿄 가부시키가이샤 Medicines for the treatment of kidney disease
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
CN109890379A (en) 2016-10-11 2019-06-14 拜耳制药股份公司 Combination product comprising sGC activator and mineralocorticoid receptor antagonists
WO2018069126A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc stimulators and mineralocorticoid receptor antagonists
CN109863137A (en) 2016-10-26 2019-06-07 星座制药公司 LSD1 inhibitor and its medical usage
WO2018153898A1 (en) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selective partial adenosine a1 receptor agonists in combination with mineralocorticoid receptor antagonists
DE102017008472A1 (en) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Combination containing PDE5 inhibitors and mineralocorticoid receptor antagonists
CN111867582A (en) 2018-03-14 2020-10-30 爱尔兰詹森科学公司 Capsid assembly modulator dosing regimen
KR20210130753A (en) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Amide derivatives useful for the treatment of HBV infection or HBV-induced disease
WO2021078135A1 (en) 2019-10-25 2021-04-29 广东东阳光药业有限公司 Pyrrole amide compound and use thereof
RU2738405C1 (en) * 2020-05-26 2020-12-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Amide (e)-2-amino-4-oxo-5-(2-oxo-2-phenylethylidene)-1-(3-ethoxycarbonyl)-4,5,6-7-tetrahydrobenzo[b]thiophen-2-yl)4,5-dihydro-1h-pyrrole-3-carboxylic acid, having antimicrobial activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058249A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators
US20040267028A1 (en) * 2001-09-24 2004-12-30 Smith Roger A Preparation and use of pyrrole derivatives for treating obesity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8008732A (en) * 1979-06-28 1981-04-28 Ciba Geigy Ag STABILIZERS FOR CHLORINATED THERMOPLASTIC COMPOUNDS
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JPH07116139B2 (en) 1986-06-09 1995-12-13 三菱化学株式会社 Method for producing lactams
DE3717068A1 (en) * 1987-05-21 1988-12-08 Basf Ag 4-SUBSTITUTED 10-CYANMETHYLENE PYRROLO (4,3-E) -BENZO-AZEPINE
JPH04145078A (en) 1990-10-04 1992-05-19 Hokko Chem Ind Co Ltd Pyrroledicarboxylic acid derivative and herbicide
JPH10251258A (en) * 1997-03-14 1998-09-22 Suntory Ltd Pyrroloazepine-based compound
DE19719585A1 (en) * 1997-05-09 1998-11-12 Hoechst Ag New N-sulphonyl-di:amino:carboxylic acid derivatives
WO1999036068A1 (en) * 1998-01-14 1999-07-22 Nippon Shinyaku Co., Ltd. Potassium channel activators
WO1999050264A1 (en) * 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
GB9817548D0 (en) * 1998-08-12 1998-10-07 Novartis Ag Organic compounds
BR9915194A (en) * 1998-11-09 2001-08-07 Black James Foundation Compound, method for making the same, pharmaceutical composition, and method for making the same
ES2234564T3 (en) * 1999-02-10 2005-07-01 Mitsubishi Pharma Corporation AMIDA TYPE COMPOUNDS AND THEIR USE IN MEDICINE.
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
UA76475C2 (en) 2001-07-19 2006-08-15 Pharmacia Corp Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system
WO2003007955A2 (en) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US20070010562A1 (en) 2001-08-13 2007-01-11 Ulrike Bauer Nr1h4 nuclear receptor binding compounds
WO2003015777A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
DE60131967D1 (en) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4 nuclear receptor binding compounds
DE10148328A1 (en) 2001-09-29 2003-04-10 Bayerische Motoren Werke Ag Method for positioning a motor vehicle steering wheel
US7078430B2 (en) * 2002-07-08 2006-07-18 Ranbaxy Laboratories Limited HMG CoA-reductase inhibitors
MXPA05001688A (en) * 2002-08-12 2005-04-19 Sugen Inc 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors.
EP1398029A1 (en) * 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
CN1485072A (en) 2002-09-28 2004-03-31 李大鹏 Coix seed oil soft capsule for curing prostate diseases and the application thereof
US20040102511A1 (en) 2002-11-21 2004-05-27 Jitendra Sattigeri Substituted pyrrole derivatives
CA2511905A1 (en) * 2003-01-02 2004-07-22 F. Hoffmann-La Roche Ag Novel cb 1 receptor inverse agonists
AU2003298227A1 (en) 2003-01-02 2004-07-29 F. Hoffmann-La Roche Ag Novel cb 1 receptour inverse agonists
JP4703649B2 (en) * 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド Pyrrole derivatives as pharmaceutical agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040267028A1 (en) * 2001-09-24 2004-12-30 Smith Roger A Preparation and use of pyrrole derivatives for treating obesity
WO2004058249A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators

Also Published As

Publication number Publication date
DK1773768T3 (en) 2018-11-26
BRPI0513677A (en) 2007-11-27
ES2697524T3 (en) 2019-01-24
WO2006012642A2 (en) 2006-02-02
NO20070910L (en) 2007-04-26
LT1773768T (en) 2018-11-26
CA2573426A1 (en) 2006-02-02
IL180630A (en) 2013-08-29
BRPI0513677B1 (en) 2020-12-01
KR101155288B1 (en) 2012-07-02
PT1773768T (en) 2018-11-30
CA2573426C (en) 2015-11-17
AU2005266890A1 (en) 2006-02-02
RU2470916C2 (en) 2012-12-27
CY1120922T1 (en) 2019-12-11
US20110301128A1 (en) 2011-12-08
NO344324B1 (en) 2019-11-04
HUE041596T2 (en) 2019-05-28
EP1773768B1 (en) 2018-08-22
BRPI0513677B8 (en) 2021-05-25
US8026237B2 (en) 2011-09-27
RU2007107388A (en) 2008-09-10
AU2005266890B2 (en) 2011-10-06
AU2005266890B9 (en) 2014-05-08
JP2010077166A (en) 2010-04-08
PL1773768T3 (en) 2019-03-29
JP2008508308A (en) 2008-03-21
SG155188A1 (en) 2009-09-30
SI1773768T1 (en) 2018-12-31
NZ552632A (en) 2010-11-26
IL180630D0 (en) 2007-06-03
KR20070045283A (en) 2007-05-02
JP4703649B2 (en) 2011-06-15
EP1773768A4 (en) 2008-08-06
US8367667B2 (en) 2013-02-05
US20080234270A1 (en) 2008-09-25
EP1773768A2 (en) 2007-04-18
EP1773768B8 (en) 2018-12-26
AU2005266890C1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2005009387A3 (en) Azepine derivatives as pharmaceutical agents
WO2007109120A3 (en) Imidazolothiazole compounds for the treatment of disease
WO2005069865A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2009055331A3 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2007075895A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2007038669A3 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
TW200738670A (en) Novel thiophene derivatives
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2007050587A3 (en) Therapeutic compositions and methods
EA201001332A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
WO2006047032A3 (en) Indole compounds useful as serotonin selective agents
WO2005077122A3 (en) Compounds and compositions as lxr modulators

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

WWE Wipo information: entry into national phase

Ref document number: 2573426

Country of ref document: CA

Ref document number: 180630

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200700352

Country of ref document: ZA

Ref document number: 2005266890

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 552632

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005803281

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 605/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12007500256

Country of ref document: PH

Ref document number: 1200700186

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001201

Country of ref document: MX

Ref document number: 2007523832

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005266890

Country of ref document: AU

Date of ref document: 20050730

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200580026842.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005266890

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077004302

Country of ref document: KR

Ref document number: 07018563

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2007107388

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005803281

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0513677

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 11572962

Country of ref document: US